Madrigal Pharmaceuticals (MDGL) Treasury Shares (2011 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Treasury Shares of $953440.0 for Q2 2026, up 25.91% year-over-year from $757263.0 in Q2 2025, and down 0.78% quarter-over-quarter from $960898.0 in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Treasury Shares (2011 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Treasury Shares for 13 consecutive years, with $953440.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Treasury Shares rose 25.91% year-over-year to $953440.0; the TTM figure through Jun 2026 stood at $953440.0 (up 25.91% YoY), while the FY2025 annual figure was $798422.0, up 59.83% from the prior year.
- Treasury Shares fell to $953440.0 in Q2 2026 per MDGL's latest filing, from $960898.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $960898.0 in Q1 2026 and bottomed at $199125.0 in Q1 2023.
- Historically, Treasury Shares has averaged $578306.7 across 4 years, with a median of $519809.0 in 2024.
- Annual changes were most pronounced in 2024 — Treasury Shares soared 166.5% — and 2026, when it increased 25.91%.
- Madrigal Pharmaceuticals' Treasury Shares stood at $376117.0 in 2023, then surged by 32.82% to $499559.0 in 2024, then surged by 59.83% to $798422.0 in 2025, then increased by 19.42% to $953440.0 in 2026.
- Business Quant data shows MDGL's Treasury Shares at $953440.0 in Q2 2026, $960898.0 in Q1 2026, and $798422.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 953,440.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 953,440.00 |
| Jun 30, 2026 | 953,440.00 |
| Mar 31, 2026 | 141,874.00 |
| Mar 31, 2026 | 141,874.00 |
| Dec 31, 2025 | 256,488.00 |
| Dec 31, 2025 | 256,488.00 |
| Sep 30, 2025 | 779,923.00 |
| Sep 30, 2025 | 779,923.00 |
| Jun 30, 2025 | 757,263.00 |
| Jun 30, 2025 | 757,263.00 |
| Mar 31, 2025 | 694,995.00 |
| Mar 31, 2025 | 694,995.00 |
| Dec 31, 2024 | 499,559.00 |
| Dec 31, 2024 | 499,559.00 |
| Sep 30, 2024 | 502,867.00 |
| Sep 30, 2024 | 502,867.00 |
| Jun 30, 2024 | 508,947.00 |
| Jun 30, 2024 | 508,947.00 |
| Mar 31, 2024 | 530,671.00 |
| Mar 31, 2024 | 530,671.00 |